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Parkinson’s disease (PD) is a degenerative
neurologic disorder characterized by progressive
degeneration of the nigrostriatal dopaminergic
pathway that regulates body movements
(Olanow and Tatton 1999). Degeneration of
the nerve terminals in the striatum (ST) and the
neuronal cell bodies of dopamine-containing
neurons in the substantia nigra (SN) eventually
leads to the development of movement dis-
orders, including resting tremor, rigidity,
bradykinesia, and gait disturbance (Jellinger
2001). In addition to the degeneration of
dopaminergic neurons in the SN, postmortem
analysis of the brains of PD patients has fre-
quently detected the existence of cytoplasmic
inclusions in the SN neurons, also known as
Lewy bodies (Holdorff 2002; Schiller 2000).
Formation of Lewy bodies is a pathologic hall-
mark of PD and an affirmative postmortem
diagnostic marker (Takahashi and Wakabayashi
2001).
Ever since its initial description by British
physician James Parkinson in 1817, the etiol-
ogy of PD as well as the precise mechanism of
action underlying the selective destruction of
the nigrostriatal dopaminergic pathway has
remained unknown (Di Monte and Lawler
2001; Langston 2002; Mulhearn 1971).
Currently, clinical diagnosis of PD is based
on movement-related behavioral abnormali-
ties (Rao et al. 2003; Sethi 2002). However,
the absence of distinct biomarkers for the
prognosis of the disease, because of the lack of
clear understanding of the disease process, has
signiﬁcantly hampered efforts to identify and
treat PD patients early in the disease course.
At the present time, dopamine replacement
therapy using levodopa is the most widely
used approach in the treatment of clinically
diagnosed and often advanced PD patients
(Hornykiewicz 2002; Katzenschlager and
Lees 2002; Miyasaki et al. 2002). However,
the efﬁcacy of such neurotransmitter replace-
ment therapy has been limited because of
resistance and loss of response (Kostrzewa et
al. 2002; Muller 2002).
Advances made in the last several decades at
the forefront of molecular cloning, biochemical
characterization, pathology analysis, and epi-
demiologic studies have come to the general
consensus that most (> 95%) PD cases are spo-
radic and have a late onset (Tanner 2003). A
small faction (< 5%) of cases is characterized by
early onset, and these mostly occur in familial
clusters (Mizuno et al. 2001). Development of
parkinsonism syndrome in those individuals
has been attributed to mutations in several
recently identiﬁed genes, including parkin and
α-synuclein (de Silva et al. 2000; Gwinn-Hardy
2002). In contrast, development of idiopathic
PD may represent the ﬁnal outcome of a com-
plex set of interactions among the innate vul-
nerabilities of the nigrostriatal dopaminergic
system, potential genetic predisposition, and
exposure to environmental toxicants. There is
growing recognition of the role of inflam-
mation in the brain (neuroinflammation) in
the pathogenesis of PD (McGeer et al. 2001).
Neuroinflammation in the brain can be
induced by exposure to either infectious agents
or toxicants. Neuroinflammation can also
occur as a sequela to neurotoxicant-elicited
neuronal damage or injuries in the brain, a
process called reactive gliosis (Liu and Hong
2003). In this article, we review the literature
on the potential impact on the development of
idiopathic PD of environmental factors such as
exposure to infectious agents and pesticides and
early-life occurrence of brain injuries. More
important, we will attempt to establish a possi-
ble link between early-life neuroinﬂammation
and late life development of idiopathic PD.
Immune Cells in the Brain
Inﬂammation in the brain involves primarily
the activity of two types of glial cells: microglia
and astrocytes. Microglia are the resident
immune cells in the brain (del Rio-Hortega
1993). During late embryonic and early post-
natal brain remodeling and maturation,
microglia are involved in the programmed
elimination of neural cells (Barron 1995;
Milligan et al. 1991). In mature brains, rest-
ing microglia exhibit a characteristic ramiﬁed
morphology and serve the critical role of
immune surveillance. As an important line of
defense in the brain, microglia become readily
activated in response to injuries to the brain
or to immunologic stimuli (Kreutzberg 1996;
Liu and Hong 2003; Streit et al. 1988,
1999). Activated microglia undergo dramatic
morphologic changes, metamorphosing from
resting ramified microglia into activated
amoeboid microglia (Kreutzberg 1996). They
also exhibit increased expression of surface
molecules such as complement receptors and
major histocompatibility complex (MHC)
molecules (Graeber et al. 1988; Oehmichen
and Gencic 1975). At the same time, acti-
vated microglia release a variety of soluble fac-
tors. Although activated microglia are known
to produce several trophic factors (Barde
1989; Lindsay et al. 1994; Streit et al. 1999),
most of the factors released by activated
microglia are proinflammatory and poten-
tially cytotoxic.
Astrocytes, under physiologic conditions,
provide glia–neuron contact, maintain ionic
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Idiopathic Parkinson’s disease (PD) is a devastating movement disorder characterized by selective
degeneration of the nigrostriatal dopaminergic pathway. Neurodegeneration usually starts in the
ﬁfth decade of life and progresses over 5–10 years before reaching the fully symptomatic disease
state. Despite decades of intense research, the etiology of sporadic PD and the mechanism under-
lying the selective neuronal loss remain unknown. However, the late onset and slow-progressing
nature of the disease has prompted the consideration of environmental exposure to agrochemicals,
including pesticides, as a risk factor. Moreover, increasing evidence suggests that early-life occurrence
of inﬂammation in the brain, as a consequence of either brain injury or exposure to infectious agents,
may play a role in the pathogenesis of PD. Most important, there may be a self-propelling cycle of
inﬂammatory process involving brain immune cells (microglia and astrocytes) that drives the slow
yet progressive neurodegenerative process. Deciphering the molecular and cellular mechanisms gov-
erning those intricate interactions would signiﬁcantly advance our understanding of the etiology and
pathogenesis of PD and aid the development of therapeutic strategies for the treatment of the dis-
ease. Key words: bacterium, cytokine, dopamine, environmental factor, free radical, head injury,
microglia, Parkinson’s disease, pesticide, virus. Environ Health Perspect 111:1065–1073 (2003).
doi:10.1289/ehp.6361 available via http://dx.doi.org/ [Online 14 May 2003]
Research | Reviewhomeostasis, buffer excess neurotransmitters,
and secrete neurotrophic factors (Aloisi 1999;
Hansson and Ronnback 1995; Vernadakis
1988). In response to immunologic challenges
and brain injuries, astrocytes also become acti-
vated (Aloisi 1999; Tacconi 1998). In the
course of activation, astrocytes up-regulate the
expression of cell-type–speciﬁc proteins such
as the glial ﬁbrillary acidic protein (Diedrich et
al. 1987). In addition, they secrete neurotrophic
factors (Friedman et al. 1990; Lindsay et al.
1994) and several proinﬂammatory cytokines.
Microglia as the Primary
Contributor of
Proinﬂammatory and
Neurotoxic Factors
In terms of the release of proinﬂammatory and
cytotoxic factors, activated microglia differ sig-
niﬁcantly from activated astrocytes in several
respects. First, the repertoire of factors pro-
duced by activated microglia is far more com-
plex than that of activated astrocytes (Figure 1).
For example, bacterial endotoxin lipopolysac-
charide (LPS)–stimulated production of tumor
necrosis factor-α (TNF-α) appears to be lim-
ited to microglia and has not been observed in
astrocytes (Giulian and Baker 1986; Lee et al.
1993; Sawada et al. 1989). Astrocytes, but
not microglia, failed to respond to β-amyloid
peptide–stimulated production of superoxide
free radicals (Qin et al. 2002). Second, of the
factors produced by both cell types, microglia
produce a signiﬁcantly larger quantity of most
such factors than do astrocytes. For instance,
LPS-stimulated microglia produced several-fold
higher amounts of nitrite, an indicator of the
production of nitric oxide (NO), than did LPS-
stimulated astrocytes (Iravani et al. 2002; Liu et
al. 2002). Similarly, the LPS-stimulated pro-
duction of interleukin-1β (IL-1β) was far more
prominent in microglia than in astrocytes
(Fontana et al. 1982; Giulian et al. 1986;
Hetier et al. 1988; Lee et al. 1993). A notable
exception may be that activated astrocytes, as
well as activated microglia, produce abundant
quantities of prostaglandins (PGs), such as PGE
and PGD (Alaﬁatayo et al. 1994; Fontana et al.
1982; Minghetti and Levi 1995). Third, in
response to immunologic stimuli, the produc-
tion kinetics of proinﬂammatory factors is dif-
ferent. Microglia usually respond faster than
astrocytes. For example, LPS-induced produc-
tion of NO occurred within the ﬁrst 6–12 hr in
microglia, compared with a much delayed time
point (24 hr) in astrocytes (Liu et al. 2002).
Interestingly, astrocytes appear to rely on sec-
ondary responses to produce certain proinﬂam-
matory factors. For example, human astrocytes
that were insensitive to LPS stimulation
responded well to stimulation by IL-1β and
produced fair quantities of TNF-α and IL-6
(Lee et al. 1993). These observations strongly
imply that microglia, as the ﬁrst line of response
to immunologic challenges in the brain, play
the primary role in the brain inflammatory
process and therefore are, under pathologic
conditions, the predominant contributor to the
inflammation-mediated neurodegenerative
process.
Overproduction and
Accumulation of
Proinﬂammatory and
Neurotoxic Factors Are
Deleterious to Neurons
Numerous in vitro and in vivo studies have
demonstrated that the production and accumu-
lation of proinﬂammatory and cytotoxic factors
by activated glia have an impact on neurons,
inducing neurodegeneration. Neurotoxicity has
been attributed to high levels of NO (Chao et
al. 1992; Dawson et al. 1994; Gao et al. 2002b;
Gayle et al. 2002; Jeohn et al. 2000), IL-1β
(Downen et al. 1999; Gayle et al. 2002; Hu et
al. 1997; Ma et al. 2002; Wu et al. 2002), IL-6
(Ladenheim et al. 2000), TNF-α (Downen et
al. 1999; Gayle et al. 2002; McGuire et al.
2001), and reactive oxygen species (ROS) such
as superoxide anions (Gao et al. 2002a, 2002b;
Liu et al. 2000a; Qin et al. 2002; Xie et al.
2002). Besides being individually toxic to neu-
rons, NO and superoxide may form more toxic
intermediates such as peroxynitrite (Beckman
and Crow 1993; Xie et al. 2002). Individual fac-
tors also may work in concert to induce syner-
gistic neurotoxicity, a scenario that may bear a
closer resemblance to the in vivo neurodegenera-
tive process (Chao et al. 1995; Jeohn et al.
1998). Conﬂicting results have been reported
regarding the involvement of prostanoids in
inﬂammation-mediated neurodegeneration. On
the one hand, inhibitors of cyclooxygenases
and/or 5-lipoxygenase have been shown to pro-
tect neurons from inﬂammation-mediated toxi-
city (Araki et al. 2001; Klegeris and McGeer
2002). On the other hand, exogenous PGE2 has
been reported to attenuate LPS-induced neuro-
toxicity (Kim et al. 2002). Nevertheless, it is
generally believed that the accumulation of a
variety of proinﬂammatory and neurotoxic fac-
tors released from activated microglia eventually
results in neurodegeneration (Liu and Hong
2003).
In reference to dopaminergic neurodegen-
eration, it is especially important to note that
the SN dopaminergic neurons are characteristi-
cally sensitive to insults by a variety of external
factors because of their reduced antioxidant
capacity; their high content of dopamine,
melanin, and lipids that are prone to oxidation;
and potential defects in mitochondrial function
(Greenamyre et al. 1999; Jenner and Olanow
1998). Furthermore, the SN area of the brain is
particularly rich in microglia (Kim et al. 2000;
Lawson et al. 1990). Hence, SN dopaminergic
neurons, residing in a microglia-rich environ-
ment (Kim et al. 2002; Lawson et al. 1990), are
especially vulnerable to attacks imposed by
factors produced by activated microglia.
Findings Associating Brain
Inﬂammation with the
Pathogenesis of PD
The initial findings linking inflammation in
the brain with the pathogenesis of PD have
Review | Liu et al.
1066 VOLUME 111 | NUMBER 8 | June 2003 • Environmental Health Perspectives
Figure 1. Differential production of proinflammatory factors by microglia and astroglia in response to
stimulation by LPS. Abbreviations: max, maximum; O2
• –, superoxide. LPS-activated microglia and
astroglia differ in the variety, quantity, and kinetics of proinﬂammatory factors they produce. The differ-
ences may determine their contribution to the neurodegenerative process. Factors produced by acti-
vated glial cells are known to be able to induce secondary responses, in an autocrine and/or paracrine
fashion, to produce a variety of additional soluble factors.
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death 4–10 Daysbeen derived from postmortem analysis of the
nigra of PD patients. In 1988, McGeer et al.
reported the detection of large populations of
MHC [human leukocyte antigen (HLA)-
DR]-positive reactive microglia in the SN of
the PD brains they analyzed. Since then,
numerous studies have reported the detection
of significantly elevated levels of a variety of
proinflammatory factors in the SN, ST, or
cerebrospinal ﬂuid (CSF; Table 1). Those fac-
tors included components of the innate
immune response such as complement pro-
teins (Yamada et al. 1992) and cytokines such
as IL-1, IL-2, IL-6, and TNF-α (Blum-Degen
et al. 1995; Hunot et al. 1999; Mogi et al.
1994a, 1994b, 1996; Muller et al. 1998;
Stypula et al. 1996). In addition, inducible
NO synthase (iNOS)–positive glial cells also
have been detected in the midbrain region of
PD brains (Hunot et al. 1996). These observa-
tions have clearly demonstrated that inflam-
mation, particularly microglial activation, is
involved in the pathogenesis of PD. In addi-
tion, molecular genetic analysis of polymor-
phisms in the genes for IL-1, IL-6, and TNF-α
as well as the TNF-α receptor gene of PD pa-
tients and matched controls further supports
the involvement of cytokines in the pathogene-
sis of PD (Kruger et al. 2000; McGeer et al.
2002; Nishimura et al. 2000, 2001; Schulte et
al. 2002). Nevertheless, because most of the
changes were detected in the terminal stage of
the disease, it has remained an open question
whether the observed glial activation was merely
a consequence of the reactive glial response to
neuronal loss. Clearly, additional evidence will
be needed to establish that glial activation, espe-
cially microglial activation, is involved in an
earlier stage of dopaminergic neurodegeneration
during the PD pathogenetic process.
Is Exposure to Infectious
Microorganisms a Risk Factor
for PD?
For several decades, infectious agents have
been suspected to be risk factors for PD.
Epidemiologic studies have associated early-life
viral infections to postencephalitic PD; case
reports, on the other hand, tend to relate viral
infections to the development of acute parkin-
sonism (Bhatt et al. 2000; Duvoisin and Yahr
1972; Elizan and Casals 1991; Ghaemi et al.
2000; Maurizi 1985; Pradhan et al. 1999).
Experimentally, exposure of neonatal Fisher 344
rats to Japanese encephalitis virus can induce the
degeneration of SN dopaminergic neurons,
development of movement disorders resembling
human PD, and occurrence of gliosis in the SN
(Ogata et al. 1997). However, identiﬁcation of a
speciﬁc causative viral agent (DNA or antigens)
in humans has so far proven elusive (Schwartz
and Elizan 1979; Wetmur et al. 1979). It is pos-
sible that viral infections alone are not sufﬁcient
to initiate the development of idiopathic human
PD, but viral infection–associated inﬂammation
at an early stage of life may well play a role in
the pathogenesis of the disease. However, the
probability of unearthing “footprints” (i.e., viral
DNA and/or antigens) of early-life viral infec-
tions in postmortem analyses of PD brains
might be exceptionally low.
Besides viruses, infections by bacterial
pathogens have also been proposed to play a
role in the development of PD. Because of the
increased frequency of peptic ulcers observed in
some PD patients, infection by Helicobacter
pylori has been one such candidate bacterium
(Altschuler 1996). Small-scale paired-case stud-
ies appear to support the hypothesis (Charlett et
al. 1999; Dobbs et al. 2000). However, solid
evidence and experimental animal models are
lacking to establish a role for H. pylori infection
in the pathogenesis of PD. Of particular inter-
est, however, is the demonstration by Kohbata
and Beaman (1991) that mice injected with
Nocardia asteroides, a common bacterium in the
soil, developed PD-like syndromes. Although
the relevant mechanism of action remains
unknown, subsequent in vitro and in vivo stud-
ies showed that infection with one strain of
Nocardia (GUH-2) resulted in apoptotic death
of SN dopaminergic neurons (Tam et al.
2002). Although the involvement of glial cells
in the neurotoxic process was not established
(Beaman and Beaman 1993) and a serologic
case–control study could not associate Nocardia
exposure to human PD (Hubble et al. 1995;
Kohbata and Shimokawa 1993), continued
research is warranted.
Inﬂammogen-Induced
Dopaminergic
Neurodegeneration:
Experimental Models of
Inﬂammation-Related PD
To directly test the hypothesis that inﬂammation
in the brain can result in selective dopaminergic
neurodegeneration, a number of groups have
used LPS to evoke inﬂammation in the brain.
Initially, LPS was injected directly in a bolus
manner into the SN area of rat brains (Castano
et al. 1998; Hsieh et al. 2002; Iravani et al.
2002; Liu et al. 2000b; Lu et al. 2000).
Dramatic degeneration of the nigrostriatal
dopaminergic pathway was observed in those
animals receiving the LPS injections. However,
this single application–induced neurodegenera-
tion was not selective to dopaminergic neurons.
More important, inﬂammation (e.g., microglial
activation) induced by the relatively large quan-
tity of LPS (microgram levels) was too fast and
too robust to enable us to clarify the temporal
relationship between microglial activation and
dopaminergic neurodegeneration (Liu et al.
2000b). A chronic LPS infusion model was
subsequently established (Gao et al. 2002b). In
this model, LPS was chronically infused for
2 weeks at a rate of 5 ng/hr into the SN region
of rat brains using an epidermal osmotic
minipump. Maximal microglial activation
occurred in the first 2 weeks, but significant
degeneration of SN dopaminergic neurons did
not manifest until 4–6 weeks after the LPS
infusion. In in vitro studies using mesencephalic
neuron–glia cultures, inhibition of microglial
activation and reduction of the production of
microglia-derived neurotoxic factors signifi-
cantly attenuated the LPS-induced dopaminer-
gic neurodegeneration (Gao et al. 2002b; Liu et
al. 2000a). In addition to infusion of LPS into
adult rodent brains, in utero exposure of devel-
oping fetuses to LPS results in degeneration of
the nigrostriatal dopaminergic pathway in
neonates (Ling et al. 2002). These studies thus
provide a tentative mechanistic link between
the occurrence of inflammation in the brain
and dopaminergic neurodegeneration and also
provide experimental evidence to suggest that
the occurrence of neuroinﬂammation in early
life, if not an inducer by itself, may represent a
risk factor for development of PD later in life.
Traumatic Brain Injury and
Development of PD
As with the potential association of infection
with development of PD, the possible correla-
tion between the occurrence of closed head
Review | Brain inflammation and dopaminergic neurodegeneration
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Table 1. Detected indicators for microglial activation in the postmortem analysis PD brains.
Marker Location Reference
HLA-DR–positive microglia SN McGeer et al. 1988
iNOS–positive glia SN Hunot et al. 1996
Complement–positive Lewy bodies SN Yamada et al. 1992
iNOS SN Hunot et al. 1996
IL-1 SN/ST/CSF Mogi et al. 1994a
Blum-Degen et al. 1995
Hunot et al. 1999
IL-2 ST/CSF Mogi et al. 1996
Stypula et al. 1996
IL-6 ST/CSF Mogi et al. 1994a
Muller et al. 1998
Blum-Degen et al. 1995
TNF-α SN/ST/CSF Mogi et al. 1994b
Hunot et al. 1999
Interferon γ SN Hunot et al. 1999injury with PD development rests largely on
information obtained through epidemiologic
studies and physicians’ case reports (Ben-
Shlomo 1997; Factor et al. 1988). Analysis of
the medical histories of a large group of World
War II veterans pointed to an association
between the occurrence of severe antecedent
head injuries and the development of PD in
later life (Plassman et al. 2000). This notion is
supported by several other studies, including
several case–control studies, that have identi-
ﬁed head injury as a major risk factor for the
development of PD (Stern et al. 1991; Taylor
et al. 1999; Tsai et al. 2002). In contrast, sev-
eral other studies failed to establish a correla-
tion between the occurrence of head injuries
and later development of PD (Goetz and
Pappert 1992; McCann et al. 1998; Williams
et al. 1991). This contradiction may reﬂect the
difficulty of designing large-scale epidemio-
logic studies, identifying reliable parameters
for measurements, and interpreting complex
data. Nevertheless, numerous case reports have
described episodes of traumatic brain injuries
with the occurrence of an acute-phase parkin-
sonism (Bhatt et al. 1999; Nayernouri 1985) or
later life development of PD (Doder et al. 1999;
Geiger 1975; Louis et al. 1996). Worth noting
is the hypothesis of so-called “Boxer’s parkin-
sonian syndrome,” which proposes that boxers,
because of their professionally related higher
chance of suffering head injuries, appear to have
a higher incidence of Parkinson-like movement
disorders (Friedman 1989; Guterman and
Smith 1987; Unterharnscheidt 1995).
Although the mechanism underlying this
head trauma–related development of permanent
damage to the nigrostriatal pathway remains
unclear, it is possible that the initial neuronal
damage leads to the activation of glial cells,
whose activity may exacerbate the neurodegen-
erative process. This may be especially true in
late-onset cases of PD after brain injuries. Using
an animal model of closed head injury, Shohami
et al. (1997) have demonstrated signiﬁcant ele-
vations in the levels of a number of cytokines
(including IL-1, IL-6, and TNF-α) after head
injury in rats. The production and accumula-
tion of those proinﬂammatory factors may exac-
erbate the neuronal damage initially induced by
the head injury. A fundamental yet unsolved
issue, however, is the identity of the responsible
initiating factor(s) that is presumably released
from injured neurons and that stimulates the
activation of glial cells. Over the years, a variety
of soluble factors as well as cell–cell adhesion
molecules have been proposed and/or impli-
cated (Chang et al. 2000a, 2000b; Giulian and
Ingeman 1988; Giulian et al. 1991; Raivich et
al. 1999). Continued search for such factors and
elucidation of the molecular mechanism respon-
sible for the neuronal injury–induced reactive
gliosis will advance our understanding of the
complex pathogenesis of PD.
Exposure to Pesticides and
Development of PD
Exposure to agrochemicals, particularly pesti-
cides, has long been suggested as a risk factor
for PD (Barbeau et al. 1985; Engel et al.
2001; Gorell et al. 1998; Herishanu et al.
2001; Hubble et al. 1993; Petrovitch et al.
2002; Ritz and Yu 2000; Seidler et al. 1996;
Semchuk et al. 1992; Tuchsen and Jensen
2000). The identification of 1-methyl-4-
phenyl-1,2,3-tetrahydropyridine (MPTP), a
by-product of illicit heroin synthesis, as the
culprit that induced Parkinson syndromes in
humans (Langston et al. 1983) has signifi-
cantly intensiﬁed the search for environmen-
tal factors as potential causes of PD (Lewin
1985). To date, exposure to several classes of
pesticides has been reported to result in
dopaminergic neurotoxicity in animal mod-
els, and such pesticides have hence been
proposed as potential risk factors in humans
(Table 2).
The structural similarity between 1-methyl-
4-phenylpyridinium ion (MPP+), the active
metabolite of MPTP, and a common herbicide,
1,1´-dimethyl-4,4´-bypyridinium (paraquat),
prompted speculation that paraquat might be a
dopaminergic neurotoxicant. Barbeau et al.
(1985) reported that paraquat, like MPTP,
induced parkinsonian behavioral changes and
dopamine depletion in the northern leopard
frog (Rana pipiens). Subsequently, it was
reported that exposure to pesticides including
paraquat was positively correlated with
increased incidence of PD in patients in parts of
Canada (Rajput et al. 1987). Similar observa-
tions were reported in farming communities in
Taiwan (Liou et al. 1997). Research conducted
in the last decade has provided a more in-depth
understanding of the dopaminergic neurotoxic-
ity of paraquat. Intracerebral injection of
paraquat resulted in loss of SN dopaminergic
neurons, depletion of dopamine in the SN, and
an elevated response to apomorphine-induced
rotational behavior (Liou et al. 1996). The
reported effects of systemically administered
paraquat, on the other hand, have been less
consistent. For example, Brooks et al. (1999)
reported that systemic administration of
paraquat to C57BL/6 mice resulted in the loss of
SN dopaminergic neurons, degeneration of ST
dopaminergic ﬁbers, and reduced ambulatory
activity. In contrast, McCormack et al. (2002)
reported that mice that underwent repeated
systemic administration of paraquat exhibited a
selective loss of SN dopaminergic neurons
without a reduction in ST dopamine content.
Instead, enhanced dopamine synthesis in the
ST, which was attributed to a possible compen-
satory mechanism, was observed (McCormack
et al. 2002). Mechanistically, the ability of
paraquat to induce free radical formation
(Fukushima et al. 1995; Yumino et al. 2002),
facilitate α-synuclein ﬁbrillation (Uversky et al.
2001), and induce apoptotic cell death (Chun
et al. 2001) has been associated with its
dopaminergic neurotoxicity.
Another class of agrochemicals that have
been found to possess dopaminergic neurotoxi-
city is dithiocarbamate-based fungicides. Case
reports initially associated exposure to maneb,
a widely used fungicide in this class, with the
development of parkinsonism in humans
(Ferraz et al. 1988; Meco et al. 1994). A rat
model was recently created by direct infusion
of maneb into the lateral ventricles (Zhang et
al. 2003). In vitro studies indicate that the
dopaminergic neurotoxicity of maneb may be
associated with its ability to inhibit the activity
of complex III in the mitochondrial respiratory
chain (Zhang et al. 2003). Fitsanakis et al.
(2002) had earlier proposed that the dopamin-
ergic neurotoxicity of maneb might be associ-
ated with its ability to facilitate catecholamine
oxidation. Furthermore, besides being toxic to
dopaminergic neurons by itself, repeated sys-
temic administration of maneb and paraquat
to mice induced a synergistic reduction in
ST dopamine content, degeneration of SN
dopaminergic neurons, and development of
motor behavioral abnormalities (Thiruchelvam
et al. 2000a, 2000b). Neonatal exposure to
both maneb and paraquat also increased the
susceptibility of the nigrostriatal dopaminergic
system to rechallenge with the same agents
during adulthood (Thiruchelvam et al. 2002).
A third class of insecticides whose environ-
mental exposure has been associated with
increased incidence of PD includes the natu-
rally occurring and commonly used insecticide
rotenone. Rotenone is known to be a speciﬁc
inhibitor of mitochondrial complex I (Earley
and Ragan 1984). Because a defect in mito-
chondrial complex I is a well-documented fea-
ture of idiopathic PD (Swerdlow et al. 1996),
rotenone was suspected to be a dopaminergic
neurotoxin. Intracerebral application of
rotenone had earlier been shown to damage the
nigrostriatal dopaminergic pathway in rats
(Heikkila et al. 1985). Initial attempts to
systemically administer rotenone to rats resulted
in damage to ST dopaminergic ﬁbers but not
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Table 2. Pesticides and dopaminergic neurotoxicity.
Pesticide Features of toxicity Animal model
Pyridinium (paraquat) DA depletion, TH–positive neuron loss, behavior Rat
Dithiocarbamate (maneb) DA depletion, TH–positive neuron loss, behavior Rat
Complex inhibitor (rotenone) DA depletion, TH–positive neuron loss, behavior Rat, mouse
Organochlorine (dieldrin) DA depletion
Abbreviations: DA, dopamine; TH, tyrosine hydroxylase.SN dopaminergic neurons (Ferrante et al.
1997). Later attempts to acutely or subchroni-
cally administer rotenone to mice also pro-
duced only minimal damage to dopaminergic
neurons (Thiffault et al. 2000). In the last
several years, however, several groups have
demonstrated that continuous systemic admin-
istration of rotenone to rats reproduces key fea-
tures of PD, including selective degeneration of
the nigrostriatal dopaminergic system, forma-
tion of cytoplasmic inclusions in SN neurons,
and movement disorders (Alam and Schmidt
2002; Betarbet et al. 2000; Hoglinger et al.
2003). In addition, chronic and subcutaneous
administration of rotenone resulted in a highly
selective dopaminergic damage and α-synu-
clein aggregation (Sherer et al. 2003b). The
lack of agreement among these studies may
stem from differences in the route, dosage,
and/or duration of rotenone application.
Mechanistically, although earlier studies had
implied that rotenone might interfere with the
dopamine transport mechanism in the ST
(Bougria et al. 1995; Marey-Semper et al.
1993), recent studies suggest that inhibition of
mitochondrial complex I activity and facilita-
tion of α-synuclein aggregation may be closely
associated with rotenone’s selective dopaminer-
gic neurotoxicity (Betarbet et al. 2000; Lee et
al. 2002; Sherer et al. 2002; Uversky et al.
2001). It remains to be determined whether
typical human exposure to pesticides alone is
likely to account for the many cases of PD. Of
particular relevance may be the synergistic
dopaminergic neurotoxicity observed with the
combination of low levels of multiple neurotox-
icants, including rotenone and LPS (Gao et al.
2003) and paraquat and maneb (Thiruchelvam
et al. 2000b).
The fourth class of pesticides with potential
dopaminergic neurotoxic effect consists of the
organochlorine pesticides that include dieldrin.
The neurotoxic and dopamine-depleting effects
of dieldrin were initially observed in intoxicated
ducks, doves, and rats (Heinz et al. 1980;
Sharma et al. 1976; Wagner and Greene 1978).
Elevated levels of residual dieldrin also have
been detected in the brains of PD patients
(Corrigan et al. 2000; Fleming et al. 1994). In
primary mesencephalic cultures, dieldrin exhib-
ited a selective dopaminergic neurotoxicity
(Sanchez-Ramos et al. 1998) that might be
mediated by its ability to induce ROS forma-
tion and lipid peroxidation as well as by its abil-
ity to promote α-synuclein fibril formation
(Kitazawa et al. 2001; Uversky et al. 2001).
In addition to the above-mentioned organo-
chlorine pesticides, case reports have associated
development of parkinsonism with exposure to
organophosphorus insecticides (Bhatt et al.
1999; Davis et al. 1978; Muller-Vahl et al.
1999). Administration of dichlorvos or chlor-
pyrifos to rats reduced catecholamine content
and locomotor activity (Ali et al. 1979, 1980;
Karen et al. 2001). It remains to be determined
whether organophosphates, as well-characterized
inhibitors of acetylcholinesterase, possess any
selective dopaminergic neurotoxicity.
Although not used as insecticides, the
impact of polychlorinated biphenyls (PCBs),
widely used in industrial settings, on the
dopaminergic system is worth mentioning.
Postmortem analysis has revealed elevated lev-
els of PCBs in PD brain (Corrigan et al. 1998).
As with dieldrin, PCBs were found to deplete
dopamine in cell cultures and in animals
(Seegal et al. 1990). The sheer number of the
PCB structurally related analogs (Shain et al.
1991) and the broad range of their systemic
toxicity (Chu et al. 1995) have made it difﬁcult
to mechanistically associate a particular variety
of PCB with selective dopaminergic toxicity
(Choksi et al. 1997; Mariussen et al. 2001).
Two potentially important issues concern-
ing exposure to pesticides and the development
of PD in humans should be addressed. First,
elevated levels of certain pesticides found in the
brains of PD patients may be merely a reﬂec-
tion of their rural living and well-water drink-
ing. It does not constitute a cause–effect
relationship between pesticide exposure and
development of PD. Experimental models
using individual pesticides have been extremely
valuable for us to evaluate the neurotoxic
effects of those toxicants at relatively high
doses. Perhaps more relevant to the probing of
the impact of pesticides on the dopaminergic
system in humans are the studies in which
multiple agents were employed at subtoxic
concentrations, such as the combination of
rotenone and LPS and of paraquat and maneb
(Gao et al. 2003; Thiruchelvam et al. 2000b).
Clearly, additional in vitro and in vivo studies
and possibly epidemiologic studies in this
direction will be most informative.
The second issue relates to the selective
dopaminergic neurodegeneration as a result of
systemic exposure to pesticides. Current expla-
nations for the elevated vulnerability of SN
dopaminergic neurons, compared with neurons
in other regions, to oxidative insults include a
reduced antioxidant capacity, increased content
of iron, high content of oxidation-prone
dopamine, and potential defect in mitochondr-
ial complex I (Greenamyre et al. 1999; Jenner
and Olanow 1998). It remains to be deter-
mined why dopaminergic neurons in the SN,
but not those in the vicinity (i.e., ventral
tegmental area), are ﬁrst and foremost lost in
the course of the degenerative process. One
possibility could that the nature and density of
microglia in both regions may be different—
that those in the SN are more responsive (in
addition to a higher density) to stimulation by
neurotoxicants or to neuronal injuries induced
by the initial assault on neurons. Therefore, the
microgliosis, either as a result of direct stimula-
tion or as a consequence of neuronal injury,
presents a much more harmful microenviron-
ment to dopaminergic neurons in the SN. By
the same token, neurons in other brain regions
are less sensitive to the same insults, compared
with SN dopaminergic neurons. Although
experimental data are lacking to demonstrate
the nature of microglia in different brain
regions, studies have shown that, at least in
rodents, the midbrain region has a higher den-
sity of microglia than other regions examined
(Kim et al. 2000; Lawson et al. 1990).
The Role of Glial Cells in
Pesticide-Induced
Dopaminergic
Neurodegeneration
Research on the dopaminergic neurotoxicity
of pesticides has traditionally focused on
the direct effect of those agents on neurons.
However, it has recently been demonstrated
that microglia actively participate in the
rotenone-induced degeneration of dopaminer-
gic neurons in mesencephalic neuron–glia cul-
tures (Gao et al. 2002a). In the absence of
microglia, rotenone exhibited a markedly
reduced toxicity to dopaminergic neurons. In
the presence of microglia, however, low
nanomolar concentrations of rotenone were
able to activate microglia to release superoxide
free radicals and facilitate the degeneration of
dopaminergic neurons. Further studies using
enzyme inhibitors suggested that the rotenone-
induced release of superoxide was mediated by
microglial NADPH oxidase (Gao et al. 2002a),
a primary source of superoxide generation in
the immune cells of both the peripheral and the
central nervous systems (Babior 1999). The
detailed molecular mechanism responsible for
this rotenone-stimulated activation of
microglial NADPH oxidase, however, remains
to be elucidated. Nevertheless, the observation
of an active participation of microglia has sig-
niﬁcantly advanced our understanding of the
dopaminergic neurotoxicity of rotenone,
because rotenone had previously been thought
to act exclusively as an inhibitor of neuronal
mitochondrial complex I. Neuronal death was
thought to be a consequence of the inhibition
of mitochondrial complex I, which then led to
a reduction in the energy supply and subse-
quent collapse of the mitochondrial membrane
potential. In addition to the in vitro observation
for the active participation of microglia in
rotenone neurotoxicity, in rotenone-infused
rats microglial activation has recently been
reported to precede dopaminergic neurodegen-
eration (Sherer et al. 2003a).
Besides being able to activate microglia to
release free radicals, rotenone and LPS have
recently been reported to exert synergistic
dopaminergic neurotoxicity (Gao et al. 2003).
Exposure to a combination of individually non-
toxic concentrations of rotenone and LPS has
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degeneration in mesencephalic neuron–glia
cultures. The observed synergistic neurotoxicity
between a pesticide (i.e., rotenone) and an
inflammogen (i.e., LPS; Gao et al. 2003),
together with observations of synergistic neuro-
toxicity among different classes of pesticides
(i.e., paraquat and maneb; Thiruchelvam et al.
2000b), is consistent with a multifactorial
hypothesis of PD etiology. Additional studies
are needed to examine the effect of exposure to
multiple environmental neurotoxicants on the
nigrostriatal dopaminergic pathway.
Microglial Activation and
Reactive Microgliosis: A 
Self-Propelling Cycle of
Neuroinﬂammation that Fuels
the Progressive Dopaminergic
Neurodegeneration
The potential role that microglia play in the
dopaminergic neurodegenerative process sug-
gests that their contribution to the death of
dopaminergic neurons includes the release of
a variety of neurotoxic factors in response to
immunologic stimuli. Similar to macrophages,
their peripheral counterpart, microglia, as the
ﬁrst line of defense in the brain, can be directly
activated by invading pathogens.
On the other hand, it is well documented
that microglia become activated after the occur-
rence of neuronal injuries. Although a variety of
soluble factors released from injured neurons
have been proposed to be the potential stimu-
lators of reactive microgliosis (Giulian and
Ingeman 1988; Giulian et al. 1991; Raivich et
al. 1999), loss of cell–cell contact between neu-
rons and glial cells may also result in microglial
activation (Chang et al. 2000a, 2000b). For
example, Chang et al. demonstrated that neu-
rons act to suppress the reactivity of glial cells
through a potential dimerization of the neural
cell adhesion molecules expressed on the surface
of both cell types (Chang et al. 2000a, 2000b).
Neurons may be able to negatively regulate the
reactivity of glial cells through other types of
cell–cell contact such as the CD200 receptor–
ligand interaction (Neumann 2001), analogous
to CD200’s role in the negative regulation of
myeloid cells (Barclay et al. 2002). Therefore,
exposure to infectious agents such as viruses and
bacteria can directly lead to the activation of
glial cells, especially the microglia. On the other
hand, glial cells also can be activated as a reac-
tive response to neuronal injuries inﬂicted by
injuries or agents such as certain pesticides that
can directly damage neurons. Furthermore, cer-
tain environmental toxicants, such as rotenone,
can induce neuronal damage and at the same
time activate microglia. In essence, regardless of
the nature of the initiating factors, a cycle may
exist: Microglial activation leads to neurodegen-
eration; neuronal injury, in turn, leads to reac-
tive glial activation, which further exacerbates
neurodegeneration. This self-propelling cycle of
brain inﬂammation may be particularly damag-
ing to the SN dopaminergic neurons, which
reside in a microglia-rich region in the brain
and which are particularly vulnerable to oxida-
tive stress. The continuing presence of this cycle
over time—plus the possible involvement of
additional uncharacterized factors, intrinsic
and/or over many years—leads to a massive
degeneration of the nigrostriatal dopaminergic
pathway and the development of symptomatic
PD (Figure 2).
Concluding Remarks
Idiopathic PD is an age-related disease that
may represent the final outcome of interac-
tions among a variety of intrinsic and envi-
ronmental factors. Inﬂammation in the brain
clearly plays an active role in the pathogenesis
of PD. Understanding the nature of those
complex interactions may be a prerequisite for
success in our quest for effective strategies to
halt the progressive neurodegenerative process
of idiopathic PD.
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